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The Patient Protection and Affordable Care Act
(ACA) aims to expand coverage to the previously
uninsured, improve the quality of coverage, and help
eliminate inefﬁciencies in the health care market. We
evaluated the implications of ACA on the drug
industry by examining the impact on the “Dinner-
for-Three” dynamic in our health care system. We
can think of our system as an odd dinner party in
which one person pays (the insurer), one orders the
meal (the physician), and yet another eats the meal
(the patient). This dynamic requires us to examine
each stakeholder and how they interact with one
another to assess the impact of the ACA. Of the 6.7
million initial exchange enrollees, 3.8 million sub-
jects were previously uninsured. A higher percentage
of these enrollees are using their pharmacy beneﬁt,
and they are disproportionately ﬁlling prescriptions
for specialty drugs relative to those covered in
employer-sponsored plans. Formulary designs in ex-
change plans are passing on higher cost-sharing for
prescription drugs to the patient. ACA has also
resulted in the development of accountable care
organizations (ACOs); these organizations may play
a role going forward in the management of drug
spending and the development of formularies and
protocols that impact drug prescribing. Payers are
tightening control over drug spending and are ﬁnding
physicians and physician groups increasingly less
reluctant allies in doing so. Patients are faced by
more complexity than ever in the health care system
and are expected to take a more active role in
responsibly managing the cost of their care. It isAccepted for publication February 10, 2015.
http://dx.doi.org/10.1016/j.clinthera.2015.02.013
0149-2918/$ - see front matter
& 2015 The Authors. Published by Elsevier HS Journals, Inc. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
April 2015increasingly critical that drug manufacturers develop
robust value propositions and communicate that
value to all stakeholders. They should re-evaluate
trial investment decisions and consider changes in
price setting, rebates (how much and to whom),
copay programs, and physician and patient support
programs in light of changing market needs. (Clin
Ther. 2015;37:733–746) & 2015 The Authors. Pub-
lished by Elsevier HS Journals, Inc.
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President Barack Obama’s Patient Protection and
Affordable Care Act (ACA) have dominated the US
political landscape for at least the last 5 years. State-
ments about success or failure of the law are often
politically inspired and not necessarily founded in
facts. Irrespective of political positions, what are the
real implications of the various components of the
ACA on the pharmaceutical industry?
The most important elements of the ACA that
impact prescription drugs involve expansion of the
insured population, improving quality of coverage,
and eliminating inefﬁciencies. Some speciﬁc factors
include the following: Introduction of health care exchanges, aimed to
provide affordable coverage for the previously
uninsured. Expansion of Medicaid coverage up to 133% of
the federal poverty level for participating states.Scan the QR Code with your phone to obtain
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of the average manufacturer price to 23.1% of the
average manufacturer price for most drugs. Expanded health care coverage for dependents up
to age 26 years. Prohibition of annual and lifetime coverage
limitations. Various initiatives to improve quality and efﬁciency
of health care, including Medicare payment links to
quality performance, accountable care organiza-
tions (ACOs), and various bundled payment ini-
tiatives and pilots.
Expanding health care coverage and improving
health care quality are intuitively promising character-
istics that should be beneﬁcial to the drug industry.
However, how will the new insurance offerings and
ACO incentive structures affect formulary management
practices, prescribing behaviors, and patient preferen-
ces? How will they affect the prescription drug business?
In evaluating the impact of changes in a health care
system, we need to consider the complexities and the
host of stakeholders and inﬂuencers involved. Third-
party insurance of medical services and prescription
drugs create a dynamic that makes the industry unique
in that purchaser (insurance), decision maker (physi-
cian), and end customer (patient) form a much more
complex decision-making platform than the usual
buyer–seller relationship for consumer products. The
Price of Global Health (Second Edition) describes this
process as an odd “Dinner-for-Three.”1 We used this
framework to analyze and predict the impact of the
trends resulting from ACA on the US prescription
drug environment.THE CHANGING US PRESCRIPTION DRUG
MARKET
We cannot consider the impact of ACA on today’s
prescription drug environment without looking at
other market developments. Prescription drug costs
have been an increasingly “hot topic” over the last
few years, with heavy public criticism over Zaltraps
(ziv-aﬂibercept [Sanoﬁ US, Bridgewater, New Jersey])
pricing voiced by Sloan Kettering,2 a Blood article by
US hematologists over prices of hematology drugs,3
and, most recently, public and payer concerns
regarding the pricing of Sovaldis (sofosbuvir [Gilead
Sciences, Inc, Foster City, California]). Under leader-
ship of the American Society of Clinical Oncology,34medical communities have started to explore how to
take cost into consideration in clinical guideline
decision making.
Although payers are often hesitant to take action
on a cost-related issue (unless they have a solid
medical rationale), payers have shown a willingness
and conﬁdence to be more vocal about drug cost
issues, as evidenced by the public anger of Express
Scripts (ESI) regarding the Sovaldi pricing. In Decem-
ber 2014, ESI announced their decision to exclude
Gilead’s Sovaldi and combination therapy Harvonis
for hepatitis C treatment from their 2015 National
Preferred Formulary, covering only the newly ap-
proved regimen of AbbVie, Inc. Soon after, Caremark
announced their decision to list only Gilead’s therapies
and exclude AbbVie’s therapies from their national
formulary. Although these decisions do not apply to
the entire membership of the pharmacy beneﬁt man-
agers (PBMs) (eg, self-insured employers can use a
custom formulary), PBMs are demonstrating a will-
ingness to manage high-cost drugs more tightly. Care-
mark and ESI also have, for some of their plans,
removed nonpreferred anti–tumor necrosis factor
drugs from formulary rather than placing them on a
higher copay tier, allowing for only a few covered
options. One can wonder whether this action is at least
in part motivated by the extensive use of copay offset
programs (coupons) by drug manufacturers with non-
preferred brands. Coupons have been troublesome for
many payers, but they have been very selective in
combating the use of these coupons, for example, by
the introduction of step edits or prior authorizations
for nonpreferred brands.
It remains to be seen whether the formulary
exclusions for hepatitis C drugs are an exception or
a harbinger of further exclusions for new high-cost
specialty drugs. It also remains to be seen how willing
commercial health plans, beyond PBMs, are to create
exclusion lists. Although health plans have used
exclusions on their Medicaid and Medicare formula-
ries for many years, they have been less likely to do so
thus far for their commercial formularies. An impor-
tant element in this evolution is the acceptance of
limitations in prescribing choices by physicians, em-
ployers, and patients.
Outside the United States, the prescription drug
market has also been undergoing extensive changes
due to the economic recession and related budget
crises. Particularly in Europe, the euro crisis andVolume 37 Number 4
E. Schoonveld et al.resulting ﬁscal austerity measures have had a strong
impact on government decision making for reimburse-
ment of prescription drugs. This includes some funda-
mental drug review system changes in Germany,
France, and the United Kingdom.
In the United States, the cost of health care has been
a central part of the discussion for many years and an
important impetus for the ACA. The political discus-
sions have since moved to the legality of the individual
mandate and implementation challenges for the ex-
changes, but the underlying cost concerns remain a
factor of consideration.DINNER-FOR-THREE
Times are long gone that drug-prescribing decisions
were unilaterally made by individual physicians. Be-
cause 87% of US patients have insurance coverage
that includes prescription drugs, most patients do not
see the actual drug cost but are exposed to a ﬁxed
copay or percent coinsurance rate. A critique from
payers worldwide has always been that due to the role
of insurance, a natural market mechanism is lacking.
Many ex-U.S. governments have argued that because
of a lack of cost concerns by physicians and patients,
there is not enough incentive to try less expensive
options, and pharmaceutical companies can set rela-
tively high prices.
The Price of Global Health (Second Edition)1
describes this phenomenon as “Dinner-for-Three.”
Imagine 3 people go to a restaurant (Figure 1).
Decision maker (Bob) is ordering a meal from the
menu, diner (Betty) is consuming the meal, and thePayer
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Figure 1. “Dinner-for-Three” analogy. KOL = key
opinion leader. Source: The Price of
Global Health (second edition).1
April 2015payer (Bob) is settling the bill. In this context it seems
odd, but this scenario does describe the drug-
prescribing process for patients with health care
coverage. Payer Ben may argue that Betty does not
really need that champagne and caviar, but Bob and
Betty will be equally upset if Ben only allows for a hot
dog 3 times a day.
Let us step away from the dinner context and
transition to the “negotiating triangle” between payer,
physician, and patient to analyze the impact of ACA
and other recent market changes on each of the
stakeholders and their inﬂuencers, as well as the
implications for the pharmaceutical industry. We ﬁrst
analyze the details of ACA implementation as we
know them to date.
CURRENT STATUS OF EXCHANGE
ENROLLMENT
In the spring of 2014, the US Department of Health &
Human Services (HHS) reported that 8.1 million
individuals enrolled in the new exchanges, despite
the many technical implementation issues. By Novem-
ber 2014, exchange enrollment was down to 6.7
million (Table I) as many exchange enrollees did not
pay premiums, some lost coverage for not providing
proof of citizenship,4 and initial HHS estimates
included patients who only signed up for dental
coverage.
There are no conclusive statistics on the proportion
of exchange and Medicaid enrollees from the ﬁrst
enrollment period who were previously uninsured.
Initial estimates indicated a drop in uninsured to
13.4%5 or 15%,6 but later estimates provide a
different picture. The latest estimate from the Kaiser
Family Foundation, dated June 2014, is that 57% of
exchange enrollees were previously uninsured.7 The
estimate is based on a survey of 750 exchange
enrollees. In October 2014, ESI released a report
based on an actual analysis of their exchange
membership.8 They found that 66% of their
exchange enrollees were either previously uninsured
or enrolled in a prescription drug plan administered
by another carrier. However, they do not quantify the
speciﬁc percentage of enrollees who were previously
uninsured, and we can only be sure that it is o66%,
which is consistent with the Kaiser data.
Assuming the Kaiser estimate is accurate, the
exchanges have enrolled 3.8 million Americans
who were previously uninsured. This is a signiﬁcant735
Table I. Exchange enrollment history according to the US Department of Health & Human Services (HHS).
Timing HHS Estimate Reasons for Drop from Spring 2014 Estimate
Spring 2014 8.1 million NA
August 2014 7.3 million Many did not pay premiums
October 2014 7.1 million Some lost coverage for failing to provide proof of citizenship
or ﬁnancial eligibility
November 2014 6.7 million Previous estimate included 400,000 individuals
who only signed up for dental coverage
NA ¼ not applicable.
Clinical Therapeuticsnumber but represents only 8% of the estimated
47 million uninsured individuals in the United States
before the implementation of the ACA.
In addition to exchanges, many Americans have
beneﬁted from the expansion of Medicaid coverage in
participating states, as well as the expanded health
care coverage for dependents up to age 26 years.
Medicaid expansion is still evolving as several addi-
tional states have recently decided to participate.
Figure 2 shows an estimate of the US health
insurance landscape according to coverage type on
the basis of these preliminary numbers. The main
observations are that: (1) the uninsured population
has declined but is still a large population segment;Uninsured
11%
Exchanges
2%
Medicaid/
other
public 15%
Medicare
14%
Employer-
sponsored
insurance
52%
Private
nongroup
insurance
5%
Figure 2. US patient population according to
payer segment in December 2014
(estimated). Source: The Price of Glo-
bal Health (second edition).1
736and (2) the exchange population is currently relatively
small. During the second enrollment period, many
states have implemented programs to provide
enrollment support and raise awareness in target
populations. As of the ofﬁcial deadline of the second
enrollment period (February 15th, 2015), the Obama
administration reported that 11.4 million people
either re-enrolled in an exchange plan or enrolled
for the ﬁrst time.9 This number does not take in to
account that in many cases the deadline has been
extended. Final numbers will again have to be
corrected for those who have not paid their
premiums or not veriﬁed legal residency.
HHS still believes exchange enrollment will even-
tually reach 25 million but that this goal will take
until 2019, as opposed to the 2017 estimate originally
provided. Although no conclusive statistics are avail-
able, the shift from employer-based coverage or other
private plans into the exchanges has been lower than
HHS initially expected.
The ACA is likely here to stay, despite the con-
tinued legal challenges from opponents. The most
recent challenge is that the federal government, due
to speciﬁc language of the law, can provide tax
subsidies to eligible residents only from the states
running their own exchanges. Today, only 17 states
operate exchanges on their own, but most legal
scholars are skeptical that the challenge will be upheld
in federal court.STATUS OF EXCHANGE PRESCRIPTION DRUG
COVERAGE
The ESI report states that 49% of ESI’s exchange
enrollees who signed up for coverage during the ﬁrstVolume 37 Number 4
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Figure 3. Exchange enrollment according to plan
type (after first enrollment period).
Source: HHS Estimate.10
E. Schoonveld et al.enrollment period had already used their pharmacy
beneﬁt.8 This ﬁgure is nearly as high as the proportion
for their commercially insured membership (55%). As
one of the largest providers of prescription drug
beneﬁts in the country, ESI’s data are likely a good
proxy for the exchange population as a whole. The
large majority of exchange enrollees are in a Silver or
Bronze plan (Figure 3)10 with a 4-tier formulary
design. Catastrophic and Platinum plans have at-
tracted only a small share of patients.
Exchange enrollees thus far have been 59% more
likely to ﬁll a specialty medication than are commer-
cial members; for ESI, this represents 38% of spending
for exchanges compared with 28% for health plans.8
This ﬁnding is mainly due to a higher utilization for
HIV and hepatitis drugs. The high utilization of
specialty drugs may pose a signiﬁcant cost challengeTable II. Exchange cost-sharing reduction choices for
deductible reduction.
Plan Type
% That Reduced
Tier 4 Drug Cost-
Sharing
% That Red
Tier 3 Drug
Sharing
200%–250% FPL 5 13
150%–200% FPL 39 58
o150% of FPL 53 63
FPL ¼ federal poverty level.
Source: Avalere.11
April 2015for exchange plans. In this context, it is important to
consider that the government offers ﬁnancial
assistance to low-income exchange enrollees in the
form of premium credits or cost-sharing reductions.
According to HHS, 85% of the current exchange
population is enrolled in a plan with ﬁnancial assis-
tance. For the cost-sharing reduction plans, exchange
carriers have wide discretion and ﬂexibility about how
to adjust that cost-sharing, and, so far, they have been
much more likely to reduce the medical deductible
than they are to reduce the coinsurance rate for
specialty drugs.11 This leaves even the lowest income
exchange enrollees with a very high drug cost-sharing
burden (Table II). Many plans have chosen to place a
proportionally high burden on drug copayments for
patients in favor of lower medical copays. This seems
odd, given long-term cost savings of effective drugs,
but it may be explained by the relatively short-term
perspective of the plans in light of usual insurance
turnover rates and the fact that spending on specialty
drugs is one of the fastest growing categories in
health care.
Given the pressure on insurance premiums, it is not
surprising that most plans use multiple-tier formula-
ries and relatively high copay and coinsurance rates.
Avalere Health published an analysis of 603 exchange
plan designs for 2014 across 60 major carriers in 19
states.12 Their analysis included both federally
operated and state-based exchanges. According to
Avalere’s analysis, coinsurance is more common than
copays for specialty tier drugs in Bronze and Silver
plans. Table III presents the Avalere study results,
with average coinsurance rates of 37% for Bronze,
22% for Silver, and 28% for Gold plans. Coinsurancesubsidized offerings overwhelmingly favor medical
uced
Cost-
% That Reduced
Medical Beneﬁt
Deductible
% That Reduced
Primary Care
Copay
74 31
96 61
96 70
737
Table III. Average coinsurance rate and use frequency of coinsurance tiers for exchange plans.
Plan Type
Average Coinsurance
on 4th Tier
Frequency of Coinsurance
on Specialty Tier
Frequency of Copay
on Specialty Tier
No. of Plans
Assessed
Bronze 37% 75% 25% 144
Silver 22% 59% 41% 145
Gold 28% 56% 44% 111
Platinum 19% 38% 62% 49
Source: Avalere.12
Clinical Therapeuticsrates for the Avalere study, based on the plans
selected, may seem out of line for the Silver plans.
HealthPocket, a consumer information website, found
that the average coinsurance for a drug on a specialty
tier in November 2014 was 37% for a Bronze plan
and 34% for a Silver plan.13 Of the plans Avalere
assessed, 39% require coinsurance of Z40% for all
covered drugs in at least 1 specialty class, most
frequently in multiple sclerosis (MS) and oncology.12
Exchange enrollees are also subject to cost-sharing
through deductibles. For 2015, the average deductible
for a Silver plan is expected to be approximately
$3000 for an individual and $6000 for a family. Most
plans will have combined medical and pharmacy
deductibles.
It is important to consider that the ACA also has
provisions for out-of-pocket (OOP) maximums, and
many exchange enrollees could reach their maximum
in their ﬁrst or second specialty drug ﬁll. The OOP
limit is federally regulated and must conform to
speciﬁc amounts. For 2015, the OOP amount can be
no higher than $6600 for an individual plan and
$13,200 for a family plan. This includes both medical
and pharmacy claims. OOP maximums are adjusted
based on income, and thus many enrollees will see
lower limits. However, patients would still incur
several thousands of dollars in OOP costs before
hitting the limits, thus creating a “sticker shock” that
discourages them from using their beneﬁt. If enrollees
do not have a full understanding of their beneﬁts and
how OOP limits work, they may believe they will have
to pay the same high OOP expense for each prescrip-
tion reﬁll or medical encounter.
Critics of the ACA state that requiring cost-sharing
as high as Z40% for all drugs in a class goes against
the central “affordability” tenet of the law. Others738have criticized the exchange plans for their propensity
to restrict network access. A recent McKinsey Center
report concluded that about one half of the exchange
plans offer “narrow network” plans, deﬁned as plans
that have 31% to 70% of hospitals in the area in-
network.14 We should consider that there may be a
signiﬁcant group of Americans who cannot afford
their coverage at work but earn too much to be
eligible for exchange subsidies, and these individuals
are very likely to be left without coverage.
In summary, analysis to date on the coverage
characteristics for patients under the exchange plans
found that:1. A high proportion of exchange enrollees are al-
ready using their pharmacy beneﬁt.2. Specialty drug use and spending are signiﬁcantly
higher for exchange enrollees than for commer-
cially insured patients.3. For many plans, coinsurance rates for high-cost
specialty drugs exceed cost-sharing for commercial
and Medicare plans.4. Although OOP limits (which are income adjusted) can
alleviate consumer burden, sticker shock remains.5. Exchange enrollees may face other restrictions on
access above and beyond high specialty drug cost-
sharing (eg, narrow physician/hospital networks).
IMPACT OF PATIENT COST-SHARING
Patient cost-sharing was not introduced by the ACA. It is
important to consider the high cost-sharing for the new
exchange plans in the context that patients have been
subject to continuously increasing cost contributions and
multiple copayment tiers in the years before the intro-
duction of the ACA. Figure 4 illustrates the development
of the private employer-sponsored plans from 2000 toVolume 37 Number 4
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Source: Kaiser/HRET Survey of Employer Sponsored Health Benefits, 2013.15
E. Schoonveld et al.2013.15 The majority of plans used a 2-tier structure in
2000. By 2013,480% of plans hadZ3 tiers, with 4-tier
plans growing rapidly. Interestingly, the emergence of
4-tier formularies started in 2004 at the implementation
of Medicare Part D, which by design was requiring an
average 25% coinsurance rate across its drug portfolio.
Figure 5 displays the development of copay rates for
private employer-sponsored health plans within each tier
from 2000 to 2013. Copays have been rising steadily. In
the same period, coinsurance rates have been more stable,0
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April 2015but coinsurance tiers (usually tiers 4 and 5) have been
increasingly applied, as shown in Figure 4.
Increased cost-sharing through deductibles and
copayments is intended to keep premiums low and
encourage patients to make better decisions regarding
health care utilization. What are the longer term cost
implications, however? Can patients really make better
decisions when faced with a disease that is only treated
effectively by using high-cost drugs? Gleason et al16
presents an example of the impact of copaymentsTier 3
Nonpreferred)
Tier 4
(Specialty)
2000
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Clinical Therapeuticsfor an MS treatment on patient adherence. Patient
abandonment (i.e., not ﬁlling prescriptions) increased
from 5% to 425% for higher copayments (Figure 6).
Abandoning drugs that treat MS puts patients at higher
risk for relapses, hospitalization, and, in the long term,
disability.
A recent United Healthcare study found that
increased spending on drugs decreased the overall
cost of health care for patients with cancer.17 The
study assessed 810 cancer patients with breast, colon,
and lung cancer from 5 major oncology practices over
a 3-year period, and the authors examined the differ-
ence in total treatment costs when practices were
reimbursed under standard buy and bill or a fee-for-
service versus a bundled, prospective reimbursement
approach. Even though drug costs were approxi-
mately $13.5 million higher for the bundled payment
group, overall costs were 34% lower.
Similarly, the “Diabetes Ten City Challenge” study,
with ﬁrst-year results published in 2009, illustrated the
impact of pharmacist intervention and increased drug
spending on overall costs and quality.18 For the 573
patients studied, total costs were reduced by 7% versus
projection. The net 7% reduction comprised a drug
spending increase of 19% and a medical spending
decrease of 19%. Numerous outcomes were improved
as well, including reductions in glycosylated hemoglobin,
cholesterol, blood pressure, and body mass index.
A health care system’s focus on costs, as well as patient
exposure to health care costs, can be seen as dispropor-
tionately focused on drug spending, given that only 15%
of total health care spending is on drugs. Many health
care plans have a short-term focus or manage pharmacy740beneﬁts only, and they therefore may not experience the
long-term beneﬁts of increasing drug spending or decreas-
ing drug cost-sharing for their membership. This is also a
byproduct of the fact that it is easier to monitor and
control drug costs than it is to measure the impact of
drugs on long-term patient outcomes and medical costs.
High copayments should also be considered in the
context of the devastating impact that they can have
on the ﬁnances of patients with diseases such as
rheumatoid arthritis, MS, and cancer. Oncologists
have recently started to use the term “ﬁnancial
toxicity” to express the trade-off between clinical
performance and cost in decision making.
As exchange enrollments increase and the number
of patients who are exposed to high cost-sharing for
drugs is growing, we need to be concerned about
higher-than-desired abandonment, with its potential
negative impact on patient outcomes and long-term
total costs. For drug manufacturers, the promise of
increased enrollment may not yield increasing sales,
and patients may associate “fault” for high costs with
drug manufacturers rather than with insurance design.
PROGRESS WITH ACOs
Today, 4300 ACOs provide coverage to 5 million
Medicare patients.19 Government records show that,
within the ﬁrst year of the ACO program, about one
half of eligible ACOs earned bonuses for saving
Medicare money and also meeting needed quality
metrics, resulting in $705 million in total Medicare
savings.20 Program advocates view these preliminary
results as a good sign that the ACA could translate
into substantial savings if the program expands. In
reality, the program seems to mainly entice a quest for
short-term savings opportunities; an open question is
whether there will be any longer term cost and quality
impact.
The actual savings generated are small in compar-
ison to total Medicare costs, which amount to not
millions or billions, but trillions of dollars each year.
In addition, the risk for ﬁnancial penalty has already
caused many ACOs to drop out of the program. In
fact, in the latest assessment, 100 ACOs spent more
than Medicare’s expectations.19 Dean Clinic and
St. Mary’s Hospital ACO in Wisconsin is notable
for having cost Medicare $10 million more than
expected. Most ACOs have a 3-year grace period in
which they can only earn bonuses without incurring
penalties, and due to the novelty of the ACO program,Volume 37 Number 4
E. Schoonveld et al.ﬁnancial loss to date has been limited. To incentivize
continued, further participation, the federal govern-
ment proposed in early December 2014 to extend the
grace period by another 3 years. There are currently 4
different ACO programs with varying risk/savings
proﬁles to further incentivize program growth.
It remains to be seen how effective the ACO
program will be at saving money and improving
quality of care. Indeed, the sustainability of the
program as a whole is still very uncertain. We should
not take as a given that the more integrated model
will realize the promised beneﬁts or that the beneﬁts
will exceed the administrative costs. However, the
trend toward integration of provider systems and
paying for value rather than volume is likely here to
stay. Integrated systems need to be considered as a
distinct customer that requires a targeted value
proposition, with relevant quality and ﬁnancial met-
rics as part of the offering. The program’s incentives
are expected to further drive the scale and integration
of services.
For drug manufacturers, ACOs present both risks
and opportunities. From the risk side, if manufac-
turers are unable to link their drugs to overall cost-
savings or meaningfully improved outcomes relative
to comparators, risk-bearing provider groups will
likely choose lower cost options. From an opportunity
perspective, because ACOs tend to look at the overall
picture of total spending and patient outcomes, they
are likely to try and account for the complete value of
drug interventions, not just the cost.Medical
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DYNAMIC
Introduction of ACA, in combination with other
gradual changes in the health care marketplace, has
had an impact on the pharmaceutical market and its
individual decision makers and users. In terms of the
Dinner-for-Three phenomenon that was explained ear-
lier, we examine here what the likely impact is on each
of the players and then evaluate what the implications
are for the pharmaceutical industry. Figure 7 shows the
various changes in the environment that were identiﬁed
in the previous sections in the context of the Dinner-
for-Three situation.
Payers
Payers face unprecedented budget pressures, as
employers and patients criticize the cost of private
insurance plans, and political pressure is exerted with
respect to government-funded plans. ACOs offer payers
attractive opportunities to engage other stakeholders in
reducing costs, but it is unclear if the ACO model will
be fully supported by provider networks and individual
providers. Managed care plans have continued to
increase “patient responsibility” through copays and
deductibles, particularly for Medicare Part D and
exchanges, but employer-sponsored plans have also
seen recent rapid increases in coinsurance tiers, perhaps
building on the experience gained with Medicare Part D
plans in past years. Some plans, particularly PBMs,
have also been more willing to exclude drugs from
coverage even on their commercial formularies in casesPatient advocacy
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panies willing to offer attractive contracting terms.
While facing strong budget pressures, many payers are
seeing ﬁnancial upside from an inﬂux of new customers
as a result of Medicaid expansion and the creation of
exchanges. The revenue share from individual patient
policies is growing rapidly. Payers are therefore beginning
to focus increasingly on direct-to-consumer strategies (vs
business-to-business strategies) and patient experience–
related improvements, as they prepare for the likelihood
of increased turnover at the individual level and a
decrease in employer-sponsored coverage.
Physicians
Physicians are generally expected to prescribe the
best available treatment option for each patient,
irrespective of cost. Medical associations have histor-
ically provided general treatment guidelines to the
physician community, but those have generally been
sufﬁciently broad to give physicians latitude to ad-
dress speciﬁc patient conditions and needs. Cost of
treatment has, until recently, rarely been a determin-
ing factor in the guidelines.
Increasingly, medical associations are including
cost considerations in their guidelines. For example,
the American College of Cardiology and the American
Heart Association will begin characterizing treatments
with value ratings related to the cost per quality-
adjusted life-year.21
In addition, individual physicians and provider
groups have been forced to focus more on cost.
Contracting with insurance companies continues to
be a challenge, especially as some plans move to
narrow their networks. Mandated and negotiated cuts
in reimbursement for ofﬁce-administered drugs re-
quire practices to carefully consider ﬁnancials associ-
ated with drug administration. The emergence of
ACOs, payment models based on episodes of care,
and new requirements for electronic medical records
have further increased the complexity of the ﬁnancial
trade-offs for providers and potentially expose them
to the adverse selection paradigm that payers have
long faced. For example, as physicians are held
accountable for total spending and outcomes, will
they consider screening out higher risk, sicker, or less
compliant patients? Even if ACO payment schemes
take into account case mix and adjust for risk,
physicians may initially be concerned as to the
appropriateness of such adjustments. Furthermore,742as their patients are exposed to higher cost-sharing,
and the types of plan designs proliferate, physicians
and staff will need to expend more time and energy
making drug and treatment choices that are in the best
clinical and ﬁnancial interest of their patients.
As the burden associated with running the business
has increased for providers, many have joined large
groups and provider systems. Although this can free
providers from administrative burdens associated
with running their own practice, it tends to mean
that they must more actively consider group policies
and protocols, thus limiting their autonomy. For
those that remain in private practice, maintaining
the practice’s ﬁnancial health will require more
attention than ever.
Patients
Over the last few decades, patients have become
more empowered to at least participate in health care
decisions. Medical websites gain high trafﬁc, and
patients with chronic diseases can be well informed
about the disease and its treatment choices. New
digital health software and data analytics technologies
are generating more transparency and insight to
patients about the delivery and costs of their care.
As a consequence, physicians continue to evolve from
being an autocratic decision maker toward becoming
a health consultant. At the same time, employers are
increasingly leveraging ﬁnancial penalties for workers
who do not participate in wellness programs, and
payers are giving more “responsibility” to patients in
terms of higher ﬁnancial contributions through pre-
miums, deductibles, and copayments. In response
to nonpreferred copay and coinsurance rates, drug
companies have introduced copay offset programs
(coupons).
How well will patients be able to play an active role
in the decision-making process with increasingly
restrictive provider networks and multiple treatment
choices with differences in copays and availability of
coupons? Although medical information is available
in abundance through the Internet, understanding and
deciphering how insurance plans work (and with
which providers and for which drugs) can be intim-
idating even for the most educated of health care
consumers. Add into the mix the emotional turmoil
that comes with diagnosis of a serious disease, and it
can be overwhelming for patients to be at the center of
treatment decisions.Volume 37 Number 4
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Prescription drug companies have learned to assess the
inﬂuence that payers have on physician prescribing and
patient fulﬁllment by considering them as an inte-
grated system. Figure 8 illustrates the Dinner-for-Three
relationships with an example of attributes and deci-
sions that payers, patients, and physicians make.1
It might immediately be apparent from this illus-
tration that physicians have to deal with coverage
decisions as imposed by a complex group of commer-
cial payers, Medicaid, Medicare, and now the health
care exchanges. The commercial model includes many
employer-sponsored plans. Similarly, there are many
options for exchanges and Medicare Advantage or
Part D plans in most states. The payer environment is
highly fragmented and complex, and physicians are
unlikely to know the speciﬁc insurance plan offerings
for each patient and thus will only learn of any
problems after a pharmacist calls or a patient
complains.Competitive data results 
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through a direct request for a brand or through a
perceived or direct request for a drug with a lower
copayment. In the ofﬁce, a physician may be hesitant to
prescribe a higher cost drug option to a patient after
receiving multiple patient complaints and relatively good
results with a less expensive drug. In the absence of good
information, physician prescribing will be guided by his or
her judgment on patient willingness to copay and general
experience regarding copay levels to inform a decision.
In summary, the introduction of ACA is further
building on and accelerating ongoing trends in the
Dinner-for-Three dynamic of the US prescription drug
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7guidelines, and growing individual patient concerns
regarding high deductibles and copayments.3. Patients are generally better informed about treatment
options, but they are also faced with tougher choices
as complexity of the health insurance market and level
of copayments and deductibles keep increasing.4. The dynamic between payers, physicians, and
patients is increasingly inﬂuenced by other stake-
holders, such as media, medical organizations, and
government incentive programs.
IMPLICATIONS FOR DRUG COMPANIES
Although drug manufacturers can model payer–physi-
cian–patient dynamics to help make the right pricing,
rebating, and copay card decisions, what else must
they consider? Figure 7 presents the US environmental
changes discussed in the context of the Dinner-for-
Three dynamic. Inﬂuencers of the dynamic between
payers, physicians, and patients (eg, medical associa-
tions, treatment centers, patient advocacy groups,
ACOs, media) will require emphasis of a drug’s value
proposition and beneﬁts provided that are of impor-
tance from their particular perspectives.
Value Proposition
We have previously discussed how the Dinner-for-
Three relationship historically has contributed to a
lack of natural market mechanism, with limited
incentives for patients and physicians to try less
expensive options. However, we can think of the
growth of technology, patient empowerment, and
physician ﬁnancial incentives as continuing to “shift
the balance” in decision-making roles and responsi-
bilities for our Dinner-for-Three participants. A drug
manufacturer’s ability to charge premium pricing for
innovative drugs has become increasingly dependent
on value as perceived by patients and physicians
rather than just payers.
Drug manufacturers need to ensure that their value
proposition is compelling to all key stakeholders, includ-
ing not just payers, prescribers, and patients but also their
representing organizations. Depending on the speciﬁc
situation, additional stakeholders such as media, provider
groups, ACOs, and others need to be considered.
Speciﬁc aspects of the value proposition requirements
include several prescriber, patient, and payer propositions.
Prescriber and patient value propositions will need to
articulate why the drug is “worth” paying for (ie, copays).
For providers, this means continuing to provide a strong44clinical rationale but also helping them articulate to
patients why the drug is “worth it.” Providers will need
resources to help patients address cost burdens (including
coupons and patient support services). For patients, this
means describing clinical beneﬁts in patient-relevant ways,
including patient-relevant endpoints in trials and by
providing potentially customizable resources that help
address cost burden or manage treatment, and perhaps
even resources that help patients understand their insur-
ance coverage. Payers, including provider organizations,
require clinical and health outcomes trial data that help
justify costs relative to other options. It is important to
consider the perspective of each payer (ie, PBMs will be
more focused on drug cost-savings than medical cost
offsets). A good understanding of ﬁnancial perspectives
and incentives (ie, “follow the money”) is essential.
Value Communication
As the role of a broader group of inﬂuencers is
making the coverage and prescribing process more
complex, drug companies need to take a broader view
on value communication needs. Particularly for high-
cost specialty drugs, drug companies need to address
general value proposition in the context of price, as
well as the appropriate patient population to facilitate
medical community consensus on appropriate use: For highly “visible” disease areas, it is important
to develop value messaging for the broader public
and media that help avoid pricing controversies at
launch. For drugs with a potential for broad application, it
is important to clearly formulate intended position-
ing. This must be based on the value proposition
provided and must be credible to the medical
community on the basis of the evidence provided.
The latter can only be successfully achieved
through early and implicit consideration of the
payer’s value proposition and evidence needs dur-
ing early stages of drug development.
Given the high stakes of acceptance of drug price
and intended use, it is critical to carefully design a
communication strategy that is customized to the
individual therapy area and drug under consideration.
INVESTMENT DECISIONS
US and international market changes have implica-
tions for drug development decisions. Evidence re-
quirements, price potential, and payer coverageVolume 37 Number 4
E. Schoonveld et al.decisions will change the relative attractiveness of
individual investment opportunities and will require
changes in the marketing investment mix.AHow will the increased emphasis on value demon-
stration affect choice of new drug development
candidates, indication selection, and development
program design? How will these strategies and considerations affect the
revenue and proﬁt contribution forecasts for a drug? What prelaunch medical and marketing activities
are essential to demonstrate the need for new
treatment solutions?
CAREFULLY MONITOR MARKET EVOLUTION
The US prescription drug market is still under rapid
development, as ACA implementation is evolving in
an emotionally charged political landscape. Therefore,
it is critical to carefully monitor the continued evolu-
tion of the market: Evolution of exchange enrollment statistics and
quality of drug coverage for those enrollees. Further shift from more drug-friendly employer-
sponsored plans to exchanges over time, as employ-
ers opt out of employer-sponsored plan offerings. Willingness of other commercial plans beyond PBMs
to create exclusion lists for new high-cost specialty
drugs. Is Sovaldi an exception or a harbinger? Data systems that enable improved measurement of
outcomes and costs associated with different inter-
ventions. These could be helpful, if a drug is
delivering good value, or unhelpful, if a drug is
shown not to provide much incremental value. Technology (eg, apps, websites, tools) that help
physicians and patients quickly understand cover-
age and copay implications for available treatment
options.
Conceptually, it is hard to argue that the expansion
of coverage to uninsured populations will be a negative
for drug manufacturers. However, it is possible that the
quality of drug coverage and high OOP costs for newly
covered individuals will lead to a relatively lower
utilization of branded drugs compared with employer-
sponsored plans, and perhaps even relative to Medicare.
Thus, manufacturers will be well served to develop
good models that evaluate the payer–provider–patient
decision-making dynamic, build stronger value propo-
sitions, make well-informed access investment decisions,pril 2015communicate more effectively about price and value,
and continue to monitor the roll-out of the ACA.
Companies that are adjusting to the new realities are
likely to be best positioned to take advantage of them.REFERENCES
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